Micellar high-performance liquid chromatography (HPLC) and firstderivative ultraviolet spectrophotometry were used to simultaneously determine fluconazole (FLZ) and tinidazole (TNZ) in combined pharmaceutical dosage forms. The derivative procedure is based on the linear relationship between the drug concentration and the first derivative amplitudes at 220 and 288 nm for FLZ and TNZ, respectively. The calibration graphs were linear in the range of 1.5 -9.0 mg/mL for FLZ and 10.0-60.0 mg/mL for TNZ. Furthermore, an HPLC procedure with ultraviolet detection at 210 nm was developed. For the HPLC procedure, good chromatographic separation was achieved using an ODS C18 column (250 3 4.6 mm i.d.). The mobile phase containing 0.15M sodium dodecyl sulphate, 0.3% triethylamine and 12% n-propanol in 0.02M orthophosphoric acid at pH 5.5 was pumped at a flow rate of 1 mL/min. Indapamide was used as an internal standard. The method showed good linearity over the concentration ranges of 1.5 -30.0 and 10.0-200.0 mg/mL, with limits of detection of 0.36 and 2.70 mg/mL and limits of quantification of 1.1 and 8.2 mg/mL for FLZ and TNZ, respectively. The suggested methods were successfully applied for the simultaneous analysis of the drugs in their laboratory prepared mixture, co-formulated tablet and single dosage forms. Moreover the second method was also extended to the determination of the drugs in biological fluids.
Introduction
Fluconazole (FLZ) ( Figure 1A ) is a-(2, 4-difluorophenyl)-a-(1H-1,2,4-triazol-1-ylmethyl)-1H-1,2,4-triazole-1-ethanol (1). It is a triazole antifungal drug that inhibits cytochrome P450-dependent enzymes in sensitive fungi, resulting in impairment of ergosterol synthesis in fungal cell membranes. It is active against Blastomyces dermatitidis, Candida spp., Coccidioides immitis, Cryptococcus neoformans, Epidermophyton spp., Histoplasma capsulatum, Microsporum spp. and Trichophyton spp. (2) . Tinidazole (TNZ) ( Figure 1B ) is 1-[2-(ethylsulfonyl) ethyl]-2-methyl-nitro-1H-imidazole (1) . It has the antimicrobial actions of metronidazole and is similarly used in the treatment of susceptible protozoal infections and in the prophylaxis and treatment of anaerobic bacterial infections. It has also been used in regimens for the eradication of Helicobacter pylori in peptic ulcer disease (2) . A combination dosage form of FLZ and TNZ is used to treat the symptoms of various vaginal yeast infections, including vaginal trichomoniasis, vaginal candidiasis and bacterial vaginosis. It is proven to alleviate these symptoms by stopping the growth of the bacteria that causes the infection. It contains the active ingredients FLZ, an antifungal that halts the growth of fungi, and TNZ, an antibiotic that helps to halts the growth of bacteria.
FLZ and TNZ are the subjects of monographs in the United States Pharmacopeia (USP) (3), the British Pharmacopoeia (4) and the European Pharmacopoeia (EP) (5) .
A good guide to the research published for FLZ is presented as the comprehensive monographs in the series of Analytical Profiles of Drug Substances (6) . Several developed analytical techniques for the determination of FLZ in biological matrices and dosage form, including titration, spectrophotometry, and thinlayer, gas and liquid chromatography, were reviewed in 2011 (7) .
Reviewing the literature revealed that numerous analytical methods have been developed for the assay of TNZ, either individually or in combination with other drugs; these methods include ultraviolet (UV) spectrophotometric methods (8) (9) (10) , chromatographic methods (11) (12) (13) (14) and electrochemical methods (15) (16) (17) .
Two high-performance liquid chromatography (HPLC) methods have been reported for the simultaneous determination of FLZ and TNZ in combined tablets (18, 19) ; neither of these methods could determine the drugs in biological fluids. In addition, no UV method has been reported for the simultaneous estimation of these two drugs.
No micellar liquid chromatographic methods have yet been reported for the simultaneous determination of FLZ and TNZ in pharmaceutical preparations or in biological fluids.
Recently, interest has grown about the use of micellar mobile phases in reversed liquid chromatography (LC). In such a system, complex interactions exist (electrostatic, hydrophobic and steric) between the solute and both the stationary and mobile phases (20) . Micellar LC is an alternative method to conventional LC. The use of micellar LC is increasing for the separation of different samples due to some advantages over conventional LC, such as the low cost and low toxicity of the mobile phases due to the small amount of organic solvent employed in the mobile phases, the enhanced selectivity, rapid elution capability and simultaneous separations of hydrophobic and hydrophilic compounds as a result of the large number of interactions of the solutes with the stationary and mobile phases (21) . The solubilizing ability of micelles is one of the most important properties of this technique; in addition, it allows the direct injection of untreated samples, including biological fluids like serum and urine. The direct injection of physiological samples is feasible owing to solubilization of proteins by the micelles and monomers of surfactant. Thus, the proteins are eluted in the solvent front instead of highly retained or precipitated. In addition, the protein bound drugs are also displaced by the surfactant and released for partitioning to the stationary phase (22) .
Experimental
Apparatus Spectrophotometric analysis was conducted on a Shimadzu (Kyoto, Japan) UV-1601 PC, UV-visible double-beam spectrophotometer with matched 1 cm path-length quartz cells. The first derivative spectra of FLZ and TNZ were recorded in 1 cm quartz cells against the solvent blank in the wavelength range of 190 -400 nm using Dl ¼ 8 nm for smoothing of the spectra and scaling factor of 10.0. The ordinate maximum and minimum settings were þ0.60 and 20.70, respectively.
HPLC experiments were performed with a Shimadzu LC-20AD Prominence liquid chromatograph equipped with a Rheodyne injector valve with a 20 mL loop and an SPD-20A UV detector. Mobile phases were filtered by using a Millipore Sibata filter (Billerica, MA) and degassed by using a Prominence DGU-20A5 degasser. A Consort NV P-901 pH meter (Belgium) was used for pH measurements.
Materials and reagents
All chemicals were of analytical reagent grade and the solvents were of HPLC grade. Fluconazole was provided by LKT Laboratories (Lot 2397505). The purity percentage of FLZ was . 99.5%, as certified by an HPLC assay. Tinidazole was provided by Pfizer Company (Lot 4005129003). The purity percentage of TNZ was 99.97%; the purity was established by applying the comparison method (19) . Indapamide (IND) was used as the internal standard (IS) (Sigma-Aldrich, St. Louis, MO). Pharmaceutical preparations containing the drugs were purchased from different commercial sources in the local pharmacy. These pharmaceutical preparations were as follows: Diflucan 50 mg capsule ( produced by Pfizer Egypt S.A.E., Cairo, Egypt; under authority of Pfizer, Inc., New York, NY, labeled to contain 50 mg of FLZ, Batch 1204); Diflucan 150 mg capsule ( produced by Pfizer Egypt S.A.E.; under authority of Pfizer, Inc., labeled to contain 150 mg of FLZ, Batch 1109); Diflucan 50 mL IV ( produced by Pfizer France and packaged by Pfizer Egypt S.A.E.; under authority of Pfizer, Inc., labeled to contain 2 mg of FLZ/ mL, Batch A073902); Diflucan 70 mL syrup ( produced by Pfizer Egypt S.A.E.; under authority of Pfizer, Inc., labeled to contain 5 mg of FLZ/mL, Batch 1304); Fasigyn 500 mg tablet ( produced by Pfizer Egypt S.A.E.; under authority of Pfizer, Inc., labeled to contain 500 mg of TNZ, Batch 1001). Tablets were prepared by using 0.15 g of FLZ and 1.0 g of TNZ, 20 mg of talc powder, 15 mg of maize starch, 15 mg of lactose and 10 mg of magnesium stearate per tablet. Sodium dodecyl sulfate (SDS), 90%, triethylamine (TEA) and orthophosphoric acid, 85%, were obtained from Riedel-deHa¨en (Seelze, Germany). Methanol, n-propanol and acetonitrile (HPLC grade) were obtained from Sigma-Aldrich (Germany). Human plasma was provided by Mansoura University Hospitals (Mansoura, Egypt) and kept frozen (-58C) until use after gentle thawing. Drug free urine samples of human urine collected from healthy adults were used for the study.
Chromatographic conditions
The column was a Promosil C18 (250 Â 4.6 mm, 5 mm particle size) (Agela Technologies, Wilmington, DE). The mobile phase consisted of a mixture of 0.15M SDS, 0.3% TEA and 12% n-propanol in 0.02M orthophosphoric acid at pH 5.5 with a flow rate of 1 mL/ min. The column was operated at ambient temperature and the detector wavelength was 210 nm. IND was used as the IS.
Standard solutions
Stock solutions equivalent to 0.15 mg/mL of FLZ and 1.0 mg/mL of TNZ were prepared in methanol for both the spectrophotometric and the chromatographic method. Working solutions were prepared by appropriate dilution of the stock solutions with either methanol or the mobile phase. The solutions were stable for at least three days without alteration when kept in the refrigerator.
Procedures

Construction of calibration graphs
For the spectrophotometric method, working standard solutions of FLZ and TNZ were prepared from the previous stock solutions by serial dilutions with methanol to obtain final concentrations of 1.5 -9.0 mg/mL for FLZ and 10.0-60.0 mg/mL for TNZ. The first derivatives of the spectra were recorded. The amplitudes were measured at 220 nm for FLZ and 288 nm for TNZ.
For the HPLC method, accurately measured aliquots of the stock solutions were transferred into a series of 10 mL volumetric flasks so that the final concentrations were in the range of 1.5 -30.0 mg/mL for FLZ and 10.0 -200 mg/mL for TNZ. To each flask, 1 mL of IND stock solution was added as the IS so that the final concentration was 20 mg/mL. The solutions were completed to the volume with the mobile phase and mixed well. Aliquots of 20 mL were injected (in triplicate) and eluted with the mobile phase under the optimum chromatographic conditions. The average peak area ratio (drug/IS) versus the final concentration of the drug was plotted in mg/mL. Alternatively, the corresponding regression equations were derived.
Analysis of FLZ/TNZ synthetic mixtures
Aliquots of FLZ and TNZ standard solutions, maintaining the pharmaceutical ratio of 1.5:10.0, were transferred into a series of 10.0 mL volumetric flasks. The previously described procedure for the construction of calibration graphs was applied. The percentage recoveries were calculated by referring to the calibration graphs or by using the corresponding regression equations.
Analysis of the drugs in their laboratory prepared tablets Ten tablets were prepared, accurately weighed amounts of the powder equivalent to the weight of a single tablet of each (0.15 g of FLZ and 1.0 g of TNZ) were transferred into a 100.0 mL volumetric flask and approximately 50.0 mL of methanol were added. The contents of the flask were sonicated for 30 min, completed to the mark with the same solvent and filtered through a syringe filter. Further dilution with the same solvent was performed to produce a working standard solution to be assayed by subjecting to the previously described general procedure for the construction of calibration graphs. The nominal content was calculated either from a previously plotted calibration graph or from the corresponding regression equation.
Analysis of FLZ in capsules
An accurately weighed quantity of the mixed contents of 10 Diflucan capsules equivalent to 15.0 mg of FLZ was transferred into a 100.0 mL volumetric flask and approximately 50.0 mL of methanol were added. The contents of the flask were sonicated for 30.0 min, completed to the mark with the same solvent and filtered through a syringe filter. Further dilution with the same solvent was performed to produce a working standard solution to be assayed by subjecting to the previously described general procedure for the construction of calibration graphs. The nominal content was calculated either from a previously plotted calibration graph or from the corresponding regression equation.
Analysis of FLZ in intravenous solution
An accurately measured volume of the intravenous (IV) solution equivalent to 15.0 mg of FLZ was transferred into a clean, dry 100.0 mL volumetric flask and approximately 50.0 mL of methanol were added. The contents of the flask were sonicated for 30.0 min and completed to the mark with the same solvent. Further dilution with the same solvent was performed to produce a working standard solution to be assayed by subjecting to the previously described general procedure for the construction of calibration graphs. The nominal content was calculated either from a previously plotted calibration graph or from the corresponding regression equation.
Analysis of FLZ in syrup
An accurately measured volume of the syrup solution equivalent to 15.0 mg of FLZ was transferred into a clean, dry 100.0 mL volumetric flask and approximately 50.0 mL of methanol were added. The contents of the flask were sonicated for 30.0 min, completed to the mark with the same solvent and filtered through a syringe filter. Further dilution with the same solvent was performed to produce a working standard solution to be assayed by subjecting to the previously described general procedure for the construction of calibration graphs. The nominal content was calculated either from a previously plotted calibration graph or from the corresponding regression equation.
Analysis of TNZ in urine
Aliquots of the TNZ working standard solution were transferred into a series of 10.0 mL volumetric flasks; the final concentration was in the range of 10.0 -30.0 mg/mL. To each flask, IND was added as an IS so that the final concentration was 20.0 mg/mL. The contents of the flasks were diluted to approximately 8.0 mL with the mobile phase ( pH 5.5). One milliliter of human urine was added to each flask and the volumes were completed to the mark with the mobile phase and mixed well. Aliquots of 20.0 mL were injected (in triplicate) and eluted with the mobile phase under the reported chromatographic conditions. A blank experiment was simultaneously conducted. The peak area ratio was plotted versus the concentration of the drug in mg/mL.
Analysis of FLZ in urine
Aliquots of the FLZ working standard solution were transferred into a series of 10.0 mL volumetric flasks; the final concentration was in the range of 12.0 -24.0 mg/mL. The contents of the flasks were diluted to approximately 8.0 mL with the mobile phase ( pH 3.0). One milliliter of human urine was added to each flask and the volumes were completed to the mark with the mobile phase and mixed well. Aliquots of 20.0 mL were injected (in triplicate) and eluted with the mobile phase under the reported chromatographic conditions. A blank experiment was simultaneously conducted. The peak area was plotted versus the concentration of the drug in mg/mL.
Analysis of FLZ and TNZ in spiked human plasma Aliquots of the FLZ and TNZ working standard solutions were transferred into a series of 10.0 mL volumetric flasks; the final concentrations ranged from 1.5 -3.0 and 10.0-20.0 mg/mL, respectively. To each flask, IND was added as an IS so that the final concentration was 20.0 mg/mL. The contents of the flasks were diluted to approximately 8.0 mL with the mobile phase ( pH 3.0). One milliliter of human plasma was added to each flask and the volumes were completed to the mark with the mobile phase and mixed well. Aliquots of 20.0 mL were injected (in triplicate) and eluted with the mobile phase under the reported chromatographic conditions. A blank experiment was simultaneously conducted. The peak area ratio was plotted versus the concentration of the drug in mg/mL.
Results
First derivative spectrophotometry
Zero order absorption spectra of FLZ and TNZ showed overlapping spectra, which prevented the direct determination of either drug in the presence of the other ( Figure 2) ; therefore, first derivative was performed for the simultaneous determination of the two drugs. Figure 3 shows the first derivative spectra ( 1 D) of FLZ and TNZ. On the basis of these, FLZ can be quantified in the presence of TNZ by measuring the amplitude at the zero crossing point of 220 nm and TNZ can be quantified in the presence of FLZ by measuring the amplitude at the zero crossing point of 288 nm in the first derivative spectra, by using Dl ¼ 8. Figure 4 shows the first derivative absorption spectra of the drugs in different synthetic mixtures at their pharmaceutical ratio (1.5:10.0).
HPLC method
Optimization of the chromatographic performance and system suitability Figure 5 shows typical chromatograms for synthetic mixtures of FLZ and TNZ under the described chromatographic conditions, in which well-defined symmetrical peaks were obtained after thorough experimental trials that are summarized in the following.
Choice of column Two different columns were used for performance investigations, including a Promosil ODS 100 A column (250 Â 4.6 mm i.d., 5 mm particle size; Agela Technologies) and a Shimadzu VP-ODS column (150 Â 4.6 mm i.d., 5 mm particle size; Shimadzu).
Experimental studies revealed that the first column was the most appropriate, providing symmetrical, well defined peaks and allowing good separation of the two drugs.
Choice of appropriate wavelength
The UV absorption spectra of the methanolic solution of the studied drugs exhibited maxima at 205 nm for FLZ and 202, 228 and 309 nm for TNZ (Figure 2 ). Both drugs showed reasonable absorbance at 210 nm. Therefore, the UV detector response was set at 210 nm, which permitted the determination of both drugs in the recommended ratio.
Effect of temperature
Different column temperature settings were studied over the range of 25 -508C and it was found that increasing the column temperature resulted in an increased number of theoretical plates, but did not influence peak shape, symmetry or resolution. Therefore, room temperature was chosen as the optimum temperature for the analysis of FLZ and TNZ by the proposed method; higher temperatures were avoided for the sake of the longevity of the column. The results are shown in Table I . 
Mobile phase composition
Several modifications in the composition of the mobile phase were performed to study the possibilities of improving the performance of the chromatographic system. These modifications included the pH, the concentration of SDS, the type and concentration of the organic modifier and the flow rate. The results are shown in Table I. pH of the mobile phase Upon changing the pH of the mobile phase over the range of 3.0 -7.0, it was found that decreasing the pH increased the resolution factor, retention time and number of theoretical plates. pH 5.0 and 6.0 were optimum regarding resolution and retention time. Table I shows that pH 5.5 (intermediate between 5.0 and 6.0) was the most appropriate level, providing well resolved symmetrical peaks within a reasonable time.
Concentration of SDS
The influence of the concentration of SDS on the selectivity and retention times of the test solutes was studied using mobile phases containing concentrations of 0.02 -0.175M of SDS. Table I shows that 0.15M SDS was the most suitable concentration. The retention times of both drugs decreased (especially TNZ), whereas the symmetry of the peaks increased upon increasing the concentration of SDS. At concentrations higher than 0.15M, the solvent front interfered with the peak of TNZ.
Concentration of organic modifier
The effect of changing the percentage concentration of n-propanol on the chromatographic behavior of the test solutes was investigated in the concentration ranges of 5.0 -15.0%. It was found that the retention times of both drugs decreased upon increasing the ratio of n-propanol. The study revealed that the highest number of theoretical plates was achieved upon using 12.0% n-propanol. At concentrations higher than 12.0% (15.0%), the solvent front greatly interfered with the peak of TNZ.
Type of organic modifier Different organic solvents were tried as the modifier, including acetonitrile, methanol, n-propanol and tetrahydrofuran (THF). Methanol and acetonitrile both resulted in good resolution of the two drugs, but with increased retention time and reduced number of theoretical plates in comparison with n-propanol. THF influenced the symmetry of the FLZ peak. Therefore, n-propanol was the organic modifier of choice for optimum chromatographic separation
Flow rate
The effect of flow rate on the separation of the peaks of the compounds was studied and a flow rate of 1.0 mL/min was found to be optimal for good separation in a reasonable time. The flow rate of 1.2 mL/min was not selected because it caused the solvent front to overlap with the peak of TNZ.
Nature of internal standard
The use of different ISs was studied with ketoconazole and IND. IND was the IS of choice, which was used in a concentration of 20 mg/mL. Ketoconazole had long retention time of 15.5 min.
Validation of the method
The proposed methods were tested for linearity, specificity, accuracy and precision. Linearity Under the previously described experimental conditions, a linear relationship was established by plotting either the derivative amplitude or the peak area ratio (drug/IS) against the concentration of the drug in mg/mL for the spectrophotometric or the HPLC method. The graphs were found to be rectilinear over the concentration ranges cited in Table II . Linear regression analysis of the data produced the equations shown in the following.
Ratio first derivative spectrophotometry: (Table II) . These data proved the linearity of the calibration graph. Limits of quantitation and detection The limit of quantitation (LOQ) was determined by establishing the lowest concentration that could be measured according to ICH Q2R1 recommendations (24) , below which the calibration graph was nonlinear. The limit of detection (LOD) was determined by establishing the minimum level at which the analyte could be reliably detected (24):
where S a ¼ standard deviation of the intercept of the calibration curve and b ¼ slope of the calibration curve. LOQ and LOD values for FLZ and TNZ by the proposed methods are presented in Table II .
Accuracy and precision
To prove the accuracy of the proposed methods, the results of the assay of the drugs were compared with those of the comparison method (19) . Statistical analysis of the results using Student's t-test and variance ratio F-test (23) revealed no significant difference between the performance of the two methods regarding the accuracy and precision (Table III) .
The official methods (3) recommended a potentiometric titration for the assay of FLZ and TNZ in pure form.
Intra-day precision was performed for both methods through replicate analysis of three concentrations of the drugs on three successive times. The results are shown in Table IV .
Inter-day precision was conducted through replicate analyses of three concentrations of the drugs on three successive days. The results are summarized in Table IV .
The RSDs were found to be very small, indicating reasonable repeatability and intermediate precision of the proposed methods.
Robustness of the HPLC method
The robustness of the HPLC method was evaluated by the constancy of the peak area with the deliberate changes in the experimental parameters; these parameters included pH of the mobile phase (5.5 + 0.1), n-propanol concentration (12 + 1%, v/v) and concentration of SDS (0.15M + 0.01). These minor changes did not greatly affect the peak area ratios of either drug.
Selectivity
The selectivity of the method was investigated by observing any interference encountered from common excipients in different formulations. It was shown that these compounds did not interfere with the results of the proposed methods, except for Diflucan syrup, which could not be determined by the derivative spectrophotometric method due to interference from additives. Additionally, no interference was encountered from the human plasma matrix, although no prior extraction procedure was performed.
Pharmaceutical application
Dosage form analysis
The proposed methods were successfully applied to the simultaneous determination of FLZ and TNZ in synthetic mixtures that are medicinally recommended in the ratio of 1.5:10.0 (w/w), as with tablets (Table V) . Furthermore, the proposed methods were successfully applied to the determination of the drugs in laboratory prepared tablets (Table VI) and in single dosage forms (Table VII) . The results shown in Tables VI and VII are in good agreement with those obtained using the comparison method (19) . Statistical analysis of the results obtained using Student's t-test and variance ratio F-test (23) revealed no significant differences between the performances of the two methods regarding the accuracy and precision.
Application to biological fluid FLZ is well absorbed after oral doses; bioavailability from the oral route is 90% or more of that from the IV route. Mean peak plasma concentrations of 6.72 mg/mL have been reported in healthy subjects after a 400 mg oral dose. Peak concentrations are reached within 1 to 2 h of oral doses. Plasma concentrations are proportional to the dose over a range of 50 to 400 mg. Protein binding is only approximately 12%. Approximately 80% of a dose is excreted unchanged in the urine and approximately 11% as metabolites. The elimination half-life of fluconazole is approximately 30 h and is increased in patients with renal impairment. The pharmacokinetics of TNZ resemble those of metronidazole, although the half-life is longer. TNZ is rapidly and almost completely absorbed after oral doses; typically, a peak plasma concentration of approximately 40 mg/mL is achieved 2 h after a single 2.0 g dose, falling to approximately 10 mg/mL at 24 h and 2.5 mg/mL at 48 h; concentrations above 8 mg/mL are maintained by daily maintenance doses of 1 g. Comparable concentrations are achieved with equivalent intravenous doses. TNZ is widely distributed and concentrations similar to those in plasma have been achieved in bile, breast milk, cerebrospinal fluid, saliva and a variety of body tissues; it readily crosses the placenta. Only 12% is reported to be bound to plasma proteins. Unchanged drug and metabolites are excreted in the urine, and to a lesser extent, in the feces (2) .
Plasma and urine peaks significantly interfered with the FLZ peak at pH 5.5. However, TNZ alone could be determined in urine at that pH in the presence of IND (IS) (Figure 6 ). Under the previously described experimental conditions, a linear relationship was established by plotting the peak area ratio (drug/ Figure 6 . Application of the proposed method for the determination of TNZ in spiked human urine under the described chromatographic conditions: blank urine (A); TNZ in urine, with peaks of TNZ (30 mg/mL) (1) and IND (20 mg/mL) (2) (B). IS) against the drug concentration in mg/mL. Linear regression analysis of the data produced the following equation:
By referring to pH study, it was found that decreasing the pH would increase the retention time, so pH 3.0 was chosen to determine FLZ in urine (no IS) ( Figure 7 ) and for the simultaneous determination of both FLZ and TNZ in plasma in the presence of IND (IS) (Figure 8 ), for which linear regression analysis of the data produced the following equations: Figure 7 . Application of the proposed method for the determination of FLZ in spiked human urine under the described chromatographic conditions with change in pH to 3.0: blank urine (A); FLZ in urine, no IS, with peak of FLZ (20 mg/mL) (1) (B). There is no internal standard used at that pH and the labeled peak is the peak of FLZ (24 mg/l) in urine, the retention time of fluconazole is changed due to change in pH to 3.0. where P is the peak area ratio, A is peak area, C is the concentration of the drug in mg/mL and r is the correlation coefficient (Tables VIII and IX) .
Discussion
The present study describes two methods for the simultaneous determination of FLZ and TNZ in combined pharmaceutical dosage forms. These methods are micellar HPLC and first derivative UV spectrophotometry.
The derivative procedure is based on the linear relationship between the concentration of the drug and the first derivative amplitudes at 220 and 288 nm for FLZ and TNZ, respectively. The method permitted the quantitation of both drugs in their single dosage forms and in their co-formulated tablets.
The HPLC method permitted the separation of the two drugs with good resolution in a reasonable time, less than 7 min. The retention times for TNZ, FLZ and IND (IS) were 2.68, 3.89 and 6.14 min, respectively. It also allowed the quantitation of both drugs in their single dosage forms and in their co-formulated tablets, in addition to their simultaneous determination in spiked human plasma and the individual determination of each of the two drugs in spiked human urine.
Conclusion
The proposed methods for the simultaneous determination of FLZ and TNZ were shown to be reliable, simple, accurate and precise. In addition, they could be applied to the analysis of both drugs in co-formulated tablets. The good validation criteria of the proposed methods allow their use in quality control laboratories. The HPLC method also offers the possibility to determine the drugs in biological fluids. 
